Anti-Cdk2 [AN21.2]

Catalogue number: 151245 Sub-type: Primary antibody

Images:

Contributor

Inventor: Julian Gannon

Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories

Images:

Tool details

*FOR RESEARCH USE ONLY

Name: Anti-Cdk2 [AN21.2]

ols.org Alternate name: Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; P33 Protein Kinase;

CDKN2; CDC2-Related Protein Kinase; P33(CDK2)

Class: Monoclonal

Conjugate: Unconjugated

Description: AN21.2 is useful as a general CDK antibody since it reacts with both Cdk1 and Cdk2.

Purpose: Parental cell: Organism: Tissue: Model: Gender:

Isotype: IgG2a

Reactivity: Human; Mouse; Xenopus laevis

Selectivity: Host: Mouse

Immunogen: Human recombinant Cdk2

Immunogen UNIPROT ID:

Sequence:

Growth properties: Production details:

Formulation:

Recommended controls: Bacterial resistance: Selectable markers:

Additional notes:

Target details

Target: Cyclin-dependent kinase 2 (cdk2)

Target alternate names:

Target background: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.

Molecular weight:

Ic50:

Applications

Application: ELISA; WB

rormat: Liquid
Concentration: 1 mg/ml
Passage number:
Growth medium:
Temper **Temperature: Atmosphere:** Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide Storage conditions: -15° C to -25° C Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References: Syafrizayanti et al. 2017. Sci Rep. 7:39756. PMID: 28045055. ; Personalised proteome analysis by means of protein microarrays made from individual patient samples.; Chang et al. 2016. J Formos Med Assoc. :. PMID: 27773559. ; Immunophenotypic and genetic characteristics of diffuse

large B-cell lymphoma in Taiwan.; Chu et al. 2016. Journal of Fn Foods. 23:614-627; Xu et al. 2010. Biol Pharm Bull. 33(5):743-51. PMID: 20460749.; Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting.; Ottewell et al. 2009. Mol Cancer Ther. 8(10):2821-32. PMID: 19789217.; Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

